Physician profile
Ke-Qin Hu
NPI 1548340607
$239,122.39
in general payments reported to CMS, 2019-2025
8 companies · $46K in 2025
The $46K reported for 2025 was more than what 85% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $10K · 2021: $28K · 2022: $32K · 2023: $31K · 2024: $41K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Consulting Fee: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Travel and Lodging: $8,810 · Food and Beverage: $4,810 · Honoraria: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,755.50 |
| Consulting Fee | $16,787.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,500.00 |
| Travel and Lodging | $8,810.45 |
| Food and Beverage | $4,810.00 |
| Honoraria | $1,080.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $133,240.42 | 2019-2025 | Vemlidy, Epclusa, Livdelzi |
| Intercept Pharmaceuticals, INC. | $58,104.62 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $36,913.26 | 2024-2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $10,318.28 | 2025 | Iqirvo |
| Glaxosmithkline, LLC. | $240.00 | 2024 | |
| Mallinckrodt Hospital Products INC. | $176.91 | 2024-2025 | Terlivaz |
| Abbvie INC. | $107.43 | 2019 | |
| Sk Life Science, INC. | $21.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ke-Qin Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.